# Indivior Pharmaceuticals Inc. (INDV) fundamentals

Data as of 2026-11-04. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $36.28, market value $4.3 billion.

## Valuation
- **P/E (trailing): 10.2×** (5-yr avg 135.2×, 3-yr avg 135.2×). Indivior Pharmaceuticals Inc. trades at 10.2× trailing earnings, well below its own five-year average of 135.2×: cheap by its own standards. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 8.0×, lower than trailing, so analysts expect earnings to grow.
- **PEG: 0.00**. A PEG of 0.00 means the P/E is low relative to expected earnings growth: the market is not paying much for that growth.
- **Price / sales: 3.1×**. Each dollar of revenue is priced at 3.1×.
- **EV / EBITDA: 7.8×**. Enterprise value is 7.8× operating earnings before depreciation, the multiple that ignores how the company is financed; below 8× is inexpensive for most sectors.
- **Free-cash-flow yield: 0.7%** (5-yr avg -0.5%). Free cash flow equals 0.7% of the market value, above its five-year average of -0.5%, so the shares are cheaper on cash than they have usually been.
- **Earnings yield: 9.8%**. The inverse of the P/E: 9.8% of the price is earned each year.

## Profitability
- **Gross margin: 85.1%**. Indivior Pharmaceuticals Inc. keeps 85.1% of revenue after the direct cost of what it sells, the kind of margin that comes with software, brands or pricing power.
- **Operating margin: 40.6%**. 40.6% of revenue is left after running the business, an exceptional level.
- **Net margin: 16.9%**. 16.9% of each dollar of sales reaches the bottom line.
- **Return on equity: -214.3%**. Return on equity is negative because earnings are negative.
- **Return on assets: 37.6%**. Each dollar of assets produces 37.6% of profit.

## Growth
- **Revenue growth (1 yr): 4.3%** (3-yr 11.2%/yr). Revenue grew 4.3% over the last year.
- **EPS growth (1 yr): 3180.0%**. Earnings per share rose 3180.0%, faster than revenue, so margins expanded or the share count shrank.

## Financial health
- **Net debt / EBITDA: 0.2×**. It would take 0.2 years of operating earnings to repay net borrowings, within the comfortable range.
- **Current ratio: 0.71** (quick 0.71). Current liabilities exceed current assets, so the company depends on ongoing cash generation or refinancing to pay the next year's bills.
- **Altman Z-score: 3.35**. A Z-score of 3.35 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 4/9**. 4 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. Indivior Pharmaceuticals Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (4 analysts). 4 analysts cover Indivior Pharmaceuticals Inc.; the consensus is strong_buy, with an average price target of $49.50 (+36% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 23.5%** (YTD 1.1%, 3-mo -2.9%). The shares are up 23.5% over twelve months including dividends.
- **From 52-week high: -15.3%** (31.1% above the low). Trading 15% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 58**. An RSI of 58 is neutral.
- **Beta (1 yr): 0.48** (volatility 34%). Beta of 0.48 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=INDV · Page: https://foliofundamentals.com/stocks/indv

Not investment advice.